What question did this study set out to answer?

June 10, 2026Open Access

Feasibility study of a behavioral lifestyle intervention for Hispanic/Latino patients with metabolic dysfunction-associated steatotic liver disease

Key Points

This study aims to evaluate the feasibility and acceptability of a lifestyle intervention for Hispanic patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Participants were recruited from a federally qualified health center during 2022-2023.
Individuals were randomized into intervention and wait-list control groups with baseline and follow-up assessments.
The intervention involved 16 weekly group sessions adapted from the Diabetes Prevention Program.
Of 60 screened individuals, 27 were randomized (14 intervention, 13 control), with 70% retention at follow-up.
Median satisfaction among participants was 26, indicating moderate acceptability of the intervention.
Improvements in MASLD perceptions and behaviors were observed in the intervention group compared to the control, though not statistically significant.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) can lead to longer-term adverse health outcomes if left unmanaged, including liver failure and liver cancer. Hispanic adults have the highest rates of MASLD of any U.S. racial/ethnic subgroup. The most effective treatment is weight loss, through healthy dietary changes and increased physical activity. This study conducted 2022–2023 aimed to assess the feasibility and acceptability (primary), as well as exploratory effectiveness outcomes, of a behavioral lifestyle intervention for Hispanic patients with MASLD. Participants were recruited from a federally qualified health center. Self-administered questionnaires assessed demographic, psychosocial and behavioral variables. Staff measured height and weight. Individuals were randomized into intervention or wait-list control groups. The intervention, Healthy Liver/Hígado Sano, is adapted from the Diabetes Prevention Program and involves 16 weekly, group-delivered sessions. We assessed feasibility and acceptability of delivering the program in partnership with a clinic, as well as summary statistics at baseline and follow-up. We calculated between-group differences in change between the two groups for exploratory effectiveness outcomes using two-sample t-tests and chi-square tests, as appropriate. Of the 60 individuals screened, 45 were eligible (75%). Of these, 33 consented (73%) and 27 completed baseline data collection (60%) and were randomized, 13 to the wait-list control (usual care) and 14 to intervention condition. At follow-up, 19 of the 27 randomized (70%) were retained. Average age was 48.5 and 46.6 years in control and intervention groups, respectively. Most were female (84.6% control, 85.7% intervention) and had low acculturation (92–93%). Median satisfaction was 26 (of potential range 8–32), suggesting moderate acceptability among participants who completed follow-up. For exploratory effectiveness outcomes, while not statistically significant, intervention participants showed greater improvements in MASLD illness perception, treatment efficacy, social support, healthy eating index, and walking MET-minutes as compared to the control group. Recruitment was feasible and participants found the intervention acceptable, though improvements are needed for retention. Findings will inform future trial implementation and refinement. This study was registered at clinicaltrials.gov (NCT05200585) on January 6, 2022.

KI fragen

Bookmark

View Full Paper